Verition Fund Management LLC Amylyx Pharmaceuticals, Inc. Transaction History

Verition Fund Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $841,822 - $1.09 Million	46,561 Added 21.06%	267,694 $4.9 Million
Q2 2023 Aug 14, 2023	SELL	$20.98 - $31.42 $9,755 - $14,610	-465 Reduced 0.21%	221,133 $4.77 Million
Q1 2023 May 15, 2023	SELL	$27.71 - $40.93 $1.08 Million - $1.59 Million	-38,953 Reduced 14.95%	221,598 $6.5 Million
Q4 2022 Feb 14, 2023	SELL	$29.75 - $39.26 $1.54 Million - $2.04 Million	-51,865 Reduced 16.6%	260,551 $9.63 Million
Q3 2022 Jan 18, 2023	SELL	$17.15 - $30.92 $3 Million - $5.4 Million	-174,701 Reduced 35.86%	312,416 $8.8 Million
Q3 2022 Nov 14, 2022	SELL	$17.15 - $30.92 $7.94 Million - $14.3 Million	-463,012 Reduced 48.73%	487,117 $13.7 Million
Q2 2022 Aug 30, 2022	BUY	$6.85 - $19.93 $3.34 Million - $9.71 Million	487,053 Added 105.18%	950,129 $18.3 Million
Q2 2022 Aug 15, 2022	SELL	$6.85 - $19.93 $3.17 Million - $9.21 Million	-462,277 Reduced 49.96%	463,076 $8.92 Million
Q1 2022 Jun 02, 2022	BUY	$12.85 - $32.9 $6.26 Million - $16 Million	487,053 Added 111.12%	925,353 $11.9 Million
Q1 2022 May 13, 2022	BUY	$12.85 - $32.9 $5.63 Million - $14.4 Million	438,300 New	438,300 $5.63 Million

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $308M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

Stay updated on Verition Fund Management LLC with notifications on news.